Advanced search
Publication Cover
Cancer Investigation Volume 12, 1994 - Issue sup1
Submit an article Journal homepage
6
Views
0
CrossRef citations to date
0
Altmetric
Abstracts Article

Abstracts

Pages 1-64 | Published online: 11 Jun 2009

References

References

  • Coltman CA, et al: CHOP is curative in 30% of patients with large cell lymphoma: a 12 year SWOG follow up. In Advances in Cancer Chemotherapy: Update on Treatment for Diffuse Lymphoma (Skarin AT, ed.), pp. 71-77. Park Row, New York, 1986.
  • Klimo P, et al: MACOB B chemotherapy for the treatment of diffuse large cell lymphoma. Ann Intern Med 102:102, 1985.
  • Gordon LI, et al: Comparison of a second generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkins lymphoma. N Engl J Med 327: 1342, 1992.
  • Fisher RI, et al: Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced nonHodgkins lymphoma. N Engl J Med 328:328, 1993.
  • Tirelli LJ,et al: A phase II trial of Teniposide (VM 26) in advanced non-Hodgkins lymphoma, with emphasis on the treatment of elderly patients. Cancer 54:54, 1984.

References

  • Koeffler P: Myelodysplatic syndromes (preleukemia). Sam Hemat 23:23–284, 1986.
  • Bennet J, Catovsky D, Daniel N, et al: Proposals for the classification of the myelodysplastic syndromes. Br J Hemat 51:189–199, 1982.
  • Jacobs R, Combleet M, Vardiman J, et al: Prognostic implications of morphology and karyotype in primary myelodysplatic syndromes. Blood 67:1765–1772, 1986.
  • Yunis J: Refined chromosome analysis as an independent prognostic indicator in de novo myelodysplatic syndromes. Blood 67:1721–1730, 1986.
  • Marcus R, Huehns E: Transfusional iron overload. Clin Lab Haematol 7:195–212, 1985.
  • Souza L, Boone T, Gabrilove J, et al: Recombinant human granulocyte colony-stimulating factor: effects on normal and leukemic myeloid cells. Science 232:61–65, 1986.
  • Antin J: Phase lIII study of recombinant human granulocytemacrophage colony-stimulating factor in aplastic anemia and myelodysplastic syndrome. Blood 72:72–705, 1988.
  • Boogaerts M, VerhoefG, Scheers W: The in-vivo effects ofGMCSF on neutrophil function in patients with myelodysplastic syndromes. Blood 76:76a, 1990.
  • Ganser A, Volkers B, Hoelzer D: Recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes-a phase I/II trial. Blood 73:31–37, 1989.
  • Negrin R: Treatment of myelodysplatic syndromes with recombinant human granulocyte colony-stimulating factor. Ann Intern Med 110:110–976, 1989.
  • Negrin R, Haeuber D, Nagler A, et al: Maintenance treatment of patients with myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor. Blood 76:36–43, 1990.
  • Schuster M, Thompson J, Larson R, et al: Randomized trial or' subcutaneous granulocyte-macrophage colony-stimulating factor (GM-CSF) versus observation in patients with myelodysplastic syndrome. Proc ASCO 9:9a, 1990.
  • Thompson J: Subcutaneous granulocyte-macrophage colonystimulating factor in patients with myelodysplastic syndrome: toxicity, pharmacokinetics, and hematological effects. J Clin Oncol 7:7–629, 1989.
  • Vadhan-RajS, Keating M, Hirtelman W, et al: Effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes. N Engl J Med 317:1545–1552, 1987.
  • Bernstein S, Gilliland D, Aster J, et al: A randomized trial of two doses of recombinant human interleukin-3 in patients with myelodysplastic syndrome. Blood 80:80a, 1992.
  • Ganser A, Seipelt G, Lindemann A, et al: Effects of human recombinant interleukin-3 in patients with myelodysplastic syndromes. Blood 76:455–462, 1990.
  • Gillio A, Castro-Malaspina H, Gasparetto C, et al: Human recombinant interleukin-3 treatment in patients with myelodysplastic syndrome and aplastic anemia. Blood 78:78a, 1991.
  • Kurzrock R, Talpaz M, Estrov Z, et al: Phase I study of recombinant human interleukin-3 in patients with bone marrow failure. J Clin Oncol 9:1241–1250, 1991.
  • Nimer S, Paquette r, Ireland P,et al: Interleukin-3 (IL-3) therapy for aplastic anemia and myelodysplastic syndromes. Blood 78:78a, 1991.
  • Gordon M, Nemunaitis J, Hoffman R, et al: Phase I trial of subcutaneous recombinant human interleukin-6 in patients with myelodysplasia and thrombocytopenia. Blood 80:80a, 1992.
  • Gaggl S, Zwierzina H, Bammer T, et al: Cytokine regulation of CFU-Meg in patients with myelodysplastic syndrome. Exp Hematol 19:19a, 1991.
  • Backx B, Broeders L, Lowenberg B: Blast colony forming cells in myelodysplastic syndromes (MDS) express defective maturation abilities. Exp Hematol 19:19a, 1991.
  • Geissler K, Valent P, Bettelheim P, et al: In vivo synergism of recombinant human interleukin-3 and recombinant human interleukin-6 on thrombopoiesis in primates. Blood 79:79, 1992.

References

  • Caligiuri MA, Zmuidzinas A, Manley T, Levine H, Smith KA, Ritz J: Functional consequences of IL-2 receptor expression on resting human lymphocytes: identification of a novel NK cell subset. J Exp Med 171:1509–1526, 1990.
  • Caligiuri M, Murray C, Soiffer RJ, Klumpp TR, Seiden M, Cochran K, Cameron C, Ish C, Buchanan L, Perillo D, Smith K, Ritz J: Extended continuous infusion of low dose recombinant IL2 in advanced cancer: prolonged immune modulation without significant toxicity. J Clin Oncol 9:2110–2119, 1991.
  • Caligiuri MA, Murray C, Robertson MJ, Wang E, Cochran K, Cameron C, Schow P, Ross ME, Klumpp TR, Soiffer RJ, Smith KA, Ritz J: Selective immune modulation of NK cells following prolonged infusions of low dose recombinant IL-2. J Clin Invest 91:123–132, 1993.
  • Matos M, Schnier G, Beecher MS, Ashman L, Williams D, Caligiuri M: Expression of a functional c-Kit receptor on a subset of human natural killer cells. J Exp Med In press.

References

  • Legha SS: Current therapy for malignant melanoma. Semin Oncol 16:16–34, 1989.
  • Falkson CI, Falkson G, Falkson HC: Improved results with the addition of interferon alfa-2b to Dacarbazine in the treatment of patients with metastatic malignant melanoma. J Cfin Onco/ 9:9–1403,1991.
  • Khayat D. Borel Ch. Benhammouda A, Tourani JM, Vuillemin E. Coubrane CI, Auclerc G, Franks C. Weil M, Banzet P: Metastatic malignant melanoma (MMM): high efficacy of chemoimmunotherapy integrating interleukin 2. Mel Res 3:3–52. 1993.
  • Legha S, Ring S. Bedikian A. Eton O. Plager C. Benjamin RS: Biochemotherapy using interleukin-2 + interferon alpha-2a (IFN) in combination with cisplatin (C), vinblastine (V) and DTIC (D) in patients with metastatic melanoma. Mel Res 3:3–32. 1993.

References

  • Fukuoka M, Niitani H, Suzuki A, et al: A phase II study of CPT-II, a new derivative of camptothecin, for previously untreated non-small cell lung cancer. 1 Clin Oncol 10:10–16, 1992.
  • Masuda N, Fukuoka M, Kusunoki Y, et al: CPT-II: a new deriv-ative of camptothecin for the treatment of refractory or relapsed small cell lung cancer. J Clin Oncol 10:1225–1229. 1992.
  • Negoro S, Fukuoka M, Niitani H, et al: Phase II study of CPT-II, a new camptothecin derivative in small cell lung cancer (SCLC). ProcAm Soc Clin Oncol 10:10, 1991 (abstract).
  • Masuda N, Fukuoka M, Takada M, et al: CPT-II in combination with cisplatin for advanced non-small cell lung cancer. J Clin Oncol 10:1775–1780, 1992.
  • Masuda N, Fukuoka M, Kusunoki Y, et al: Phase I study of irinotecan (CPT-II) and cisplatin (COOP) plus G-CSF for advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 12:12, 1993 (abstract).
  • Negoro S, Fukuoka M, Masuda N. et al: Phase I study of irinotecan (CPT-II) and etoposide (E) with G-CSF in advanced lung cancer. ProcAm Soc Clin Oncol 12:12, 1993 (abstract).
  • Shinkai T, Arioka H, Kunikane H, et al: A phase I study of CPT-II and cisplatin in combination with fixed dose of vindesine in metastatic non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 12:12, 1993 (abstract).
  • Burris III HA, Hanauske AR, Johnson RK, et al: Activity of topotecan, a new topoisomerase I inhibitor, against human tumor colony-forming units in vitro. J Natl Cancer Inst 84:1816-1820, 1992.
  • Wall JG, Burris III HA, Von Hoff DO, et al: A phase I clinical and pharmacokinetic study of the topoisomerase I inhibitor topotecan (SK&F 104864) given as an intravenous bolus every 21 days. Anti-Cancer Drugs 3:337–345, 1992.
  • Rowinsky EK, Grochow LB, Hendricks CB, et al: Phase I and pharmacologic study of topotecan: A novel topoisomerase I inhibitor. J Clin Oncol 10:647–656, 1992.
  • Burris H, Kuhn J, Wall J. et al: Early clinical trials of topotecan, a new topoisomerase I inhibitor. Ann OncoI3(suppl 1):1l8. 1992 (abstract).
  • Hochster H. Speyer J, Oratz R, et al: Topotecan 21 day contin-uous infusion-excellent tolerance of a novel schedule. Proc Am Soc Clin Oncol 12:12, 1993 (abstract).
  • Eckardt JR, Burris HA, Rodriguez GA, et al: A phase I study of the topoisomerase I and II inhibitors topotecan (T) and etoposide (E). Proc Am Soc Clin Oncol 12:12. 1993 (abstract).
  • Rothenberg ML. Burris III HA, Eckardt JR, et al: Phase 1II1 study of topotecan + cisplatin in patients with non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 12:12, 1993 (abstract).
  • Miller AA, Hargis JB, Fields S, et al: Phase I study oftopotecan and cisplatin in patients with advanced cancer (CALGB 9261). Proc Am Soc Clin Oncol 12:12. 1993 (abstract).
  • Chang AY, Gu CZ. Keng P, et al. Topotecan (T) and etoposide (E) inhibit radiation (XRT) repair differently than potential lethal damage (PLD) repair or sublethal damage (SLD) repair. Proc Am Assoc Cancer Res 33:33, 1992 (abstract).
  • Mattern M. Hofmann G, McCabe F, et al: Synergistic cell killing by ionizing radiation and topoisomerase I inhibitor toptecan (SK&F 104864). Cancer Res 51:5813–5816. 1991.

References

  • Schmid FA, Sirotnak FM, Otter GM, et al: New folate analogues of the IO-deaza-aminopterin series. Markedly increased activity of the IO-ethyl analogue compared to parent compound and methotrexate against some human tumor xenografts in nude mice. Cancer Treat Rep 69:551–553, 1985.
  • Sirotnak FM, Schmid FA, Samuels LL, et al: IO-ethyl-lO-deaza-aminopterin: structural design and biochemical, pharmacologic and antitumor properties. NCI Monogr 5:127–131, 1987.
  • Wertheim MS, Kris MG, Gralla RJ,et al: Phase I trial and clinical pharmacology study of IO-ethyl-deaza-aminopterin (lO-EDAM), Proc Am Assoc Can Res 26:26, 1985 (abstract).
  • Schornagel JM, van der Vegt S, Verweij J et al: Phase II study of edatrexate in chemotherapy-naive patients with metastatic breast cancer. Ann Oncol 3:5449–552, 1992.
  • Verweij J, Schornagel J, deMukder P, et al: Toxic dermatitis in-duced by IO-ethyl-IO-deaza-aminopterin (lO-EDAM) a novel antifolate. Cancer 77: 1910-1913, 1990.
  • Jolivet J, Scornagel JH, Pinard ME Leucovorin rescue of human cancer cell lines following edatrexate or methotrexate. Proc Am Assoc Can Res 33:33, 1992 (abstract 2457).
  • Henderson IC: Chemotherapy for advanced disease. In Breast Diseases (Harris JR, Hellman S, Henderson IC, et al: eds), pp 547-677. JB Lippincott, 1991.
  • Grunberg SM, Spears CPo Jeliffe RW, et al: Phase I clinical and pharmacokinetic study of high-dose edatrexate with leucovorin rescue. Proc ASCO 12, 1993 (abstract 417).
  • Pisters KMW, Tyson LB, Bertino JR, et al: Phase I and pharma-cokinetic study of high dose edatrexate with oral leucovorin in adults with solid tumours. Proc ASCO 12, 1993, (abstract 453).

References

  • Henderson IC, Harris JR: Principles in the management of metastatic disease. In BreastDiseases, 2nd ed (Harvis JR, Hellman S, Henderson IC, Kinne DW, eds), pp 547-677. JB Lippincolt, 1991.
  • Judson IR. Anthrapyrazoles: true successors to the anthracy-clines? Anti-Cancer Drugs 2:223–231, 1991.
  • Mansi JL. Smith IE. Talbot DC, et al: A phase II study of the an-thrapyrazole CI-941. a highly active new drug against advanced breast cancer. Br J Cancer 62:62, 1990.
  • Talbot DC, Smith IE, Mansi JL, et al: Anthrapyrazole CI94I: a highly active new agent in the treatment of advanced breast cancer. J Clin Oncol 9:2141–2147, 1991.
  • Vandenberg T, ten Bokkel Huinink W, Hedley D, et al: Proc ASCO 1993 (abstract 69).

References

  • Osterling JE: Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 145:145–097, 1991.
  • Caralona WJ, Smith OS, Ratliff TL, Dodds KM, Coplen DE, Yuan 11J, Petros JA, Andriole GL: Measurement of prostatespecific antigen in serum as a screening test for prostate cancer. New Engl J Moo 324:1156–1161, 1991.
  • Optenberg SA, Thompson 1M: Economics of screening for car-cinoma of the prostate. Urol Clin N Am 17:719–737, 1990.
  • Carter HB, Pearson JO, Metter J, Brant LJ,Chan OW, Andres R, Fozard JL, Walsh PC: Longitudinal evaluation of prostatespecific antigen levels in men with and without prostate disease. JAMA 267:2215–2220, 1991.
  • Fleming C, Wasson JH, Albertsen PC, Barry MJ, Wennberg JE: A decision analysis of alternative treatment strategies for clinically localized prostate cancer. JAMA 269:269, 1993.
  • Bast RC Jr, Klug TL, St. John E, Jenison E, Niloff JM, Lazarus H, Berkowitz RS, Leavitt T, Griffiths CT, Parker L, Zurawski VR Jr, Knapp RC: A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. New Engl J Moo 309:883–887, 1983.
  • Jacobs I, Bast RC Jr: The CA 125 tumour-associated antigen: a review of the literature. Hum Reprod 4:1–12, 1989.
  • Bast RC Jr, Siegal FP, Runowicz C, Klug TL, Zurawski VR Jr, Schonholz D, Cohen CJ, Knapp RC: Elevation of serum CA 125 prior to diagnosis of an epithelial ovarian carcinoma. Gynecol Oncol 22:115–120, 1985.
  • Zurawski VR Jr, Sjovall K, Schoenfeld DA, Broderick SF, Hall P, Bast RC Jr, Eklund G, Mattsson B, Connor RJ, Eng D, Prorok PC, Knapp RC, Einhorn N: Prospective evaluation of serum CA 125 levels in a normal population. phase I: the specificities of single and serial determinations in testing for ovarian cancer. Gynecol Oncol 36:36–299, 1990.
  • Einhorn N, Sjovall K, Knapp RC, Hall P,Scully RE, Bast RC Jr, Zurawski VR Jr: Prospective evaluation of serum CA 125 levels for early detection of ovarian cancer. Obstet GynecoI80:14–18, 1992.
  • Jacobs I, Stabile I, Bridges J, Kemsley P, Reynolds C, Grudzin-skas J, Oram 0: Multimodal approach to screening for ovarian cancer. Lancet 1:268–271, 1988.
  • Jacobs I, Oram D, Prys Davies A, et al: Screening for the prevalence of ovarian cancer in 22,000 postmenopausal women using CA 125 and ultrasound. Br Moo J (in press).
  • Xu FJ, Ramakrishnan S, Daly L, Soper IT, Berchuck A, Clarke-Pearson D, Bast RC Jr: Increased serum levels of macrophage colony-stimulating factor in ovarian cancer. Am J Obstet Gynecol 165:1356–1362, 1991.
  • Xu, F-J, Yu Y-A, Daly L, DeSombre K, Anselmino L, Hass GM, Berchuck A, Soper J, Clarke-Pearson D, Boyer C, Layfield LJ,Bast RC Jr: The OVXI radioimmunoassay complements CA 125 for predicting the presence of residual ovarian carcinoma at second look surgical surveillance procedures. J Clin Oncol (in press).
  • Woolas RP. Xu F-J, Jacobs u, Yu V-H. Daly L. Berchuck A. Soper JT. Clarke-Pearson DL. Oram DH. Bast RC Jr: Elevation of multiple serum markers in stage I ovarian cancer (submitted for publication).
  • Xu FJ, Yu V-H. Daly L, Anselmino L, Hass GM. Berchuck A. Rodriguez GC. Soper JT. Clarke-Pearson DL. Hollis D, Boyer C, Bast RC Jr: OVXI as a marker for early stage endom-etrial carcinoma (submitted for publication).

References

References

  • Delozier T et al: Proc 13 Ann Breast Cancer Symp, 1990.
  • Lluch A et al: Proc ASCO 11:11 1992 (abstract 115).
  • Canobbio L et al: Sem Oncol 16 (2, suppI4): 33-36, 1989.
  • Bruno R et al: Ann Oncol 3(suppl I): 26, 1992.
  • Romero A et al: proc ASCO 12:12, 1993 (abstract 107).
  • Weber B et al: Proc ASCO 12:12, 1993 (abstract 46).
  • Seidman A et al: Proc ASCO 11:11, 1992 (abstract 64).
  • Extra JM et al: John Libbey Publishers, Pierre Fabrie Oncologie Editors, Paris 1991:213–220.
  • Tresca P et al: Breast Cancer Res Treatment 16, 1990 (abstract 66).
  • Nabholtz JM et al: Proc ASCO 12:12, 1993 (abstract 42).
  • Cvitkovic E et al: Ann Oncol 3 (suppl I): 125, 1992.
  • Blajman et al: Proc ASCO 12:12, 1993 (abstract 170).
  • Turpin F et al: Breast Cancer Res Treatment 19:19, 1991 (abstract 48).
  • Dieras V et al: Breast Cancer Res Treatment 16, 1990 (abstract 48).
  • Kayitalire L et al: Proc ASCO 12:12, 1993 (abstract 161).
  • Ferrero JM et al: Proc ASCO 12:12, 1993 (abstract 234).
  • Chadjaa M et al: Proc ASCO 12:12, 1993(abstract 152).
  • Van Praagh I et al: Proc ASCO 12:12, 1993 (abstract 180).
  • Depierre A et al: Sem Oneal 16(2, suppl 4): 26-9, 1989.
  • LeChevalier T et al: Proc ASCO 11:11, 1992.
  • O'Rourke M et al: Proc ASCO 12:12, 1993 (abstract 1148).
  • Depierre A et al: Proc ASCO 12:12, 1993 (abstract 1138).
  • Ruchdeschal JC et al: J Clin OncoI4 (1):14-22, 1986.

References

References

References

References

  • Pawlak-Byczkowska EJ, Hansen HJ, Oion AS, Goldenberg OM: Two new monoclonal antibodies, EPB-I and EPB-2, reactive with human lymphoma. Cancer Res 49:4568–4577, 1989.
  • Murthy S, Sharkey RM, Goldenberg DM, Lee RE, Pinsky CM, Hansen HJ, and LC Swayne: Lymphoma imaging with a new technetium-99m labelled antibody, LL2. Eur J Nucl Med 19:19, 1992.
  • Goldenberg DM, Murthy S, Sharkey RM, Blend MJ, Mills GQ, and CM Pinsky: Targeting and imaging of non-Hodgkin's B-cell lymphoma with a monoclonal antibody Fab' (Tc-99m) imaging agent. Proc Amer Soc Clin Oncol 12:12, March 1993.
  • Hansen HJ, Jones AL, Sharkey RM, et al: Preclinical evaluation of an “instant” Tc-99m labeling kit for antibody imaging. Cancer Res 50:50–794, 1990.

References

  • Smalley RV, Andersen JW, Hawkins MJ,Bhide V, O'Connell MJ, Oken MM, Borden EC: Interferon alfa combined with cytotoxic chemotherapy for patients with non-Hodgkin's lymphoma. N Engl J Med 327:1336–1341, 1992.
  • Peterson BA, Petroni G, Oken MM, Ozer H: Cyclophosphamide versus cyclophosphamide plus interferon a1fa-2b in follicular low grade lymphomas: a preliminary report of an intergroup trial. ProcAm Soc Clin Oncol 12:12, 1993.

References

  • Vokes EE, Weichselbaum RR, Lippman S, Hong WK: Head and neck cancer. N Engl J Med 328:184–194, 1993.
  • Vokes EE, Weichselbaum RR: Combined modality therapy for head and neck cancer. PPO Update (in press).
  • Vokes EE, Choi KE, Schilsky RL, Moran WJ, Guarnieri CM, Weichselbaum RR, Panje WR: Cisplatin, 5-f1uorouracil and highdose leucovorin for recurrent or metastatic head and neck cancer. J Clin Oncol 6:618–626, 1988.
  • Vokes EE, Schilsky RL, Weichselbaum RR, Kozloff M, Panje WR: Neoadjuvant cisplatin, fluorouracil and high-dose leucovorin for locally advanced head and neck cancer: a clinical and pharmacologic analysis. J Clin Oncol 8:241–247, 1990.
  • Vokes EE, Weichselbaum RR, Mick R, McEvilly I-M, Haraf OJ, Panje WR: Favorable long-term survival following induction chemotherapy with PFL and concomitant chemoradiotherapy for locally advanced head and neck cancer. J Natl Cancer Inst 84:84, 1992.
  • Vokes EE, Rataln MJ, Mick R, McEvilly J-M, Haraf D, Hamasaki V, Kozloff M, Weichselbaum RR, Panje WR, Wenig B, Berezin F: Cisplatin, fluorouracil and leucovorin augmented by interferon Alfa-2B in head and neck cancer: a clinical and pharmacologic analysis. J Clin Oncol II:360-368, 1993.

References

  • Boring CC, Squires TS, Tong T: Cancer statistics, 1992. CA: Cancer Clin. 42:42, 1992.
  • Wallace DM, Hindmarsh JR, Webb IN: The role of multiple mucosal biopsies in the management of patients with bladder cancer. Br J Urol 51:535–540, 1979.
  • Farrow GM, Utz DC, Rife CC, et al: Clinical observations on sixty-nine cases of in situ carcinoma of the urinary bladder. Cancer Res 37:2794–2798, 1977.
  • Utz DC, Hanash KA, Farrow GM: The plight of the patient with carcinoma in situ of the bladder. J Urol 103:160–164, 1970.
  • Koontz WW Jr, Prout GR, Smith W, et al: The use of thio-tepa in the management of non-invasive carcinoma of the bladder. J Urol 125:307–312, 1981.
  • Larmm DL: Bacillus Calmette-Guerin immunotherapy for bladder cancer. J Urol 134:134, 1985.
  • Brosman SA: The use of bacillus Calmette-Guerin in the therapy of bladder carcinoma in situ. J Urol 134:134, 1985.
  • Herr HW, Pinsky CM, Whitmore CM Jr., Sogani PC, Oettgen HF, Melanet, RR: Long-term effect of intravesical bacillus Cal-melle-Guerin on flat carcinoma in situ of the bladder. J Urol 35:35, 1986.
  • Catalona WJ, Hudson MA, Gillen, Andriole GL, Ratliff TL: Risks and benefits of repeated courses of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer. J Urol 137:137, 1987.
  • Sarosdy MF, Larmm DL: Long-term results of intravesical bacillus Calmene-Guerin therapy for superficial bladder cancer. J Urol 142:142, 1989.
  • Larmm DL, Stogdill VD, Stogdill BJ, Crispen, RG: Complications of bacillus Calmette-Guerin immunotherapy in 1,278 patients with bladder cancer. J Urol 135:135, 1985.
  • Rawls WH, Larmm DL, Lowe BA, Crawford ED, Sarosdy MF, Montie JE, Grossman HB, Scardino PT: Fatal sepsis following intravesical BCG administration for bladder cancer: a Southwest Oncology Group Study. J Urol 144:144, 1990.
  • Williams R, Sarosdy MF, Catalona W, Chodak, G, Vogelzang N, Freiha F, Torti F: Randomized trial of high vs. low dose intra-vesical interferon alpha 2-B (lPN-A2B) treatment of bladder car-cinoma in situ (CIS). In Proceedings ofthe 24th Annual Meeting of the American Society of Clinical Oncology, p 121, 1988.
  • Glashan RW: A randomized controlled study of intravesical intron A in carcinoma in situ (CIS) of the bladder. J Urol 144:144, 1990.
  • Wierenga W: Antiviral and other bioactivities of pyrimidinones. Pharmacol Ther 30:30, 1985.
  • Lotzova E, Savary CA, Khan A, Stringfellow DA: Stimulation of natural killer cells in two random-bred strains of athymic rats by interferon-inducing pyrimidinone. J Immunol 132:132, 1984.
  • Sarosdy MF, Kierum CA: Combination immunotherapy of murine transitional cell carcinoma using BCG and an interferon-inducing pyrimidinone. J Urol 142:142, 1989.
  • Simmons WB, Reichert DR, Lucio RN, Larmm DL: Pyrimidinone interferon inducers in the treatment of murine transitional cell carcinoma. In 1978 Meeting of the American Urological Association, p 169, abstract 309, 1983.
  • Sidky VA, Borden EC, Wierenga W, Bryan GT: Inhibitory effects of interferon-inducing pyrimidinones on the growth of transplantable mouse bladder tumors. Cancer Res 46:46, 1986.
  • Sarosdy MF, Lamm DL, Williams RD, Moon TD, Flanigan RC, Crawford ED, Wilks NE, Earhart RH, Merritt JA: Phase I trial of oral bropirimine in superficial bladder cancer. J Urol 147:147, 1992.

References

  • Yeager A, Kaizer H, Santos G, Saral R, Colvin M, Stuart R, Braine H, Burke P, AAmbinder R, Bums W, Fuller D, Davis J, Karp J. Stratford W. Rowley S. Sensenbrenner L. Vogelsang G, Wingard J: Autologous bone marrow transplantation in patients with acute nonlymphocytic leukemia, using ex vivo marrow treatment with 4-hydroperoxycyclophosphamide. New Engl J Med 315:315–14,1986.
  • Philip T, Armitage JO, Spitzer G, Chauvin F, Jagannath S, Cabn JY, Colombat P, Goldstone A, Gorin N, Aesh M, Laporte JP, Maraninchi D, Pico J, Bosly A, Anderson C, Schots R, Biron P, Cabanillas F, Dicke K: High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade nonHodgkin's lymphoma. New Engl J Med 316:1493–1498, 1987.
  • Peters Wp, Shpall EJ, Jones RB, Olsen G, Bast RC, Gockerman J, Moore J: High-dose combination a1kylating agents with bone marrow support as initial treatment for metastatic breast cancer. J Clin OncoI6:1368–1375, 1988.
  • Peters Wp, Ross M, Vredenburgh 11, Meisenberg B, Marks LB, Winer E, Kurtzberg J, Bast RC, Jones R, Shpall EJ, Wu K, Rosner G, Gilbert C. Mathias B, Coniglio D. Petros W. Henderson IC, Norton L, Weiss RB, Budman D, Hurd D: High-dose chemotherapy and autologous bone marrow support after standarddose adjuvant therapy for high-risk primary breast cancer. J Clin Oncol 11:11–1143,1993.
  • Dicke KA, S, Vellekoop L, Zander A, Jagganath S, Poytiron C, Lichtiger B, Verma D, Spitzer G: Autologous transplantation in acute leukemia. Surv Synth Pathol Res 4:84–96, 1985.
  • Gorin NC, Aegerter B, Auvert G, Meloni AH, Goldstone AH, Burnett A, Carella A, Korbling M, Herve P, Maraninchi D. Lowenberg R, Verdonck LF, de Planque M, Hermans J, Helbig W, Porcellini A, Rizzoli V, Alesandrino Ep, Franklin 1M, Reiffers J, Colleselli P, Goldman 1M: Autologous bone marrow transplantation for acute myelogenous leukemia in first remission: a European survey of the role of marrow purging. Blood 75: 16061614. 1990.
  • Gribben JC, Freedman AS, Neuberg D. Roy D. Blake K. Woo S, Grossbard M, Rabinowe S, Coral F, Freeman G, Ritz J, Nadler L Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for Bcell lymphoma. New Engl J Med 325: 1525–1533, 1991.
  • Wassennan TH. Phillips TL, Ross G. Kane L: Differential protection against chemotherapeutic effects on bone marrow CFUs by WR-2721. Cancer Clin Trials 4:3–6, 1981.
  • Shpall El. Jones RB, Bast RC, Rosner G, Vandermark M, Ross M, Affronti ML, Johnston C, Eggleston S, Tepperberg M. Coniglio D, Peters WP: 4-Hydroperoxycyclophosphamide (4-HC) purging of breast cancer from the mononuclear cell fraction of bone marrow in patients receiving high-dose chemotherapy and autologous marrow support: a phase I trial. J Clin Oncol, 9: s-93, 1990.
  • Shpall EJ,Jones RB, Johnston C. Schein P, Peters WP, Seigler H: Purging of breast cancer cells from bone marrow using WR-2721 and 4-hydroperoxycyclophosphamide.P roc Amer Assoc Cancer Res 31:31, 1990.
  • Jones RB, Shpall EJ,Shogan J, Affronti ML, Coniglio D, Hart L, Halperin E, lglehart D. Moore J, Gockerman J. Bast RC Jr. Peters WP: The Duke AFM program: intensive induction chemotherapy for metastatic breast cancer. Cancer 66:66 1-436, 1990.
  • Shpall EJ,Jones RB, Johnston C, Hami L, Morgan MJ. Stemmer S, Bunn P. Shaw L, McCulloch W, Schein P: WR-2721 (Amifostine) shortens the engraftment period of 4-hydroperoxycyclophosphamide (4-HC) purged bone marrow patients receiving high-dose chemotherapy with autologous bone marrow support (ABMS). Blood 78(suppl 1): 192a. 1991.
  • Johnston CS, Shpall El. Williams S. Hami L. Jones RB, Bast RC, CeriaM, RL, Franklin W: Detection of minimal residual breast cancer in bone marrow. Prog Clin Biol Res 377537-642, 1992.
  • Berenson RJ, Andrews RG, Bensinger WL, et al: Antigen CD34 + marrow cells engraft lethally irradiated baboons. J Clin Invest 81:951–955, 1988.
  • Andrews RG, Singer JW. Bernstein ID. Monoclonal antibody 12-8 recognized a 115-kd molecule present on both unipotent and multipotent hematopoietic colony-forming cells and their precursors. Blood 67:67–842, 1986.
  • Shpall EJ,Jones RB, Franklin W, Curiel T, Bearman S1, Stemmer S, Hami L. Petsche D, Taffs s, Heimfeld S, Hallagan J, Berenson RJ: CD34 + marrow and/or peripheral blood progenitor cells provide effective hematopoietic reconstitution of breast cancer patients following high-dose chemotherapy with autologous hematopoietic progenitor cell support. Blood 8024a, 1992.
  • Shpall EJ,Jones RB, Franklin W, Bearrnan S, Stemmer S, Hami L, Petsche D, Taffs S, Myers S, Purdy M, Heimfeld S, Hallagan I, Berenson RJ: Transplantation of autologous CD34+ hematopoietic progenitor cells into breast cancer patients following high-dose chemotherapy. Proc Am Soc Clin Oncol 12:12(220), 1993.
  • Hami LS, Shpall EJ,Johnston CS, Berenson R, Jones RB: The effect of Pixy-32 I on 4-Hydroperoxycyclophosphamide purged and CD34+ positively selected bone marrow. Prog Clin Biol Res 377:321–326, 1992.
  • Vredenburgh JJ, Shpall EJ, Ross M, Meisenberg B, Qler C, Tepperberg M, Eggleston S, Peters WP: Immunopharmacologic bone marrow purging and high dose chemotherapy with autologous bone marrow support (ABMS) for patients with metastatic breast cancer. Proc. Am. Soc. Clin. Oncol 11:11, 1992.
  • Shpall EJ, Jones RB, Johnston C, Hami L, Stemmer S, Affronti ML, Curiel T, Berenson R. Purified CD34 positive marrow progenitor cells provide effective reconstitution for breast cancer and Non-Hodgkins lymphoma patients receiving high dose chemotherapy with autologous bone marrow support: Recombinant Granulocyte Colony Stimulating Factor (G-CSF) accelerates hematopoietic recovery. Proc Amer Soc Clin Oncol 1159, 1992.
  • Shpall EJ,Jones RB, Johnston C, Hami L, Morgan MJ, Stemmer S, Bunn P, Shaw L, McCulloch W, Schein P. WR-2721 (Amifostine) shortens the engraftment period of 4-hydroperoxycyclophosphamide (4-HC) purged bone marrow patients receiving high-dose chemotherapy with autologous bone marrow support (ABMS). Blood 78(suppl I): 192a, 1991.

BIBLIOGRAPHY

  • Fisherman J, McCage M, Hillig M, et al: Phase I study of taxol and doxorubicin (DOX) with G-eSF in previously untreated metastatic breast cancer (MBC). Proc 28th Annual Meeting Am Soc Clin Oncl, May 17-19, 1992, 11:11 (abstract 54).
  • Holmes FA, Frye D, Valero V, et al: Phase I study of taxol (T) and doxorubicin (D) with G-CSF in patients (pt) without prior chemotherapy (Cf) for metastatic breast cancer (MBC). Proc 28th Annual Meeting Amer Soc Clin Oncol, May 17-19, 1992, 11:11 (abstract 66).
  • Holmes FA, Walters RS, Theriault RI, et al: Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 83:1797–1805, 1991.
  • Rowinsky EK, Cazenave LA, Donehower RC: Taxol: A novel investigational antimicrotubule agent. J Natl Cancer Inst 82;1247-1259, 1990.
  • Seidman A, Reichman B, Crown J, et al: Activity of taxol with recombinant granulocyte colony stimulating factor (GCSF) as first chemotherapy (C) of patients (pts) with metastatic breast cancer (MBC). Proc 28th Annual Meeting Am Soc Clin Oncol, May 17-19, 1992, 1159 (abstract 64).

BIBLIOGRAPHY

  • Chang AY, Kim K, Glick GT, Anderson T, Karp D, Johnson D: Phase II study of taxol, merbarone, and piroxantrone in stage IV nonsmall cell lung cancer: the Eastern Cooperative Oncology Group results. J Natl Cancer Inst 85:388–394, 1993.
  • Murphy WK, Fossella FV, Wirn RG, et al: Phase II study of taxol in patients with untreated advanced non-small cell lung cancer. J Natl Cancer Inst 85:384–388, 1993.
  • Rowinsky EK, Cazenave LA, Donehower RC: Taxol: a novel investigational antimicrotubule agent. J Natl Cancer Inst 82:1247–1259, 1990.

BIBLIOGRAPHY

  • Aapro M, Pujade-Lauraine E, Lhomme C, Lentz M-A, LeBail N, Fumoleaup, ChevallierB:PhaseII studyofTaxotereinovariancan· cer. Proc ASCO 12:12, 1993.
  • Bissery MC, Guenard D, Gueritte-Vogelein F, Lavelle F. Experimental anti-tumor activity of Taxotere, a taxol analogue. Cancer Res 51:4845–4852, 1991.
  • Bissett D, SetanoiansA, CassidyJ, GrahamMA, Chadwick P,Wilson p, AuzannetV,LeBailN,KayeSB,Kerr OJ:PhaseIandpharma-cokineticstudyofTaxotere(RP56976)administeredas a 24-hour infusion. Cancer Res 53:523–527, 1993.
  • Burris HA, Irvin R, Kuhn J, Kalter S, Smith L, Schaffer D, Fields, S, Weiss G, Eckardt J, Rodriguez G, Rinaldi D, Wall J, Vreeland F, Bayssas M, LeBail N, Von Hoff D: Phase I clinical trial of Taxotere given as either a 2-hour or a 6-hour infusion. J Clin Oncol 11:950–958, 1993.
  • Extra J-M, RousseauF,BrunoR,ClavelM,LebailN,MartyM.Phase J and pharmacokineticstudy of Taxotere(RP 56076; NSC 628503) given as a short intravenous infusion. Cancer Res 53:1037–1042, 1993.
  • Kavanagh JJ, Kudelka AP, Freedman RS, Edwards CL Pazdur R, Bellet R, Bayssas M, Finnegan MB, Newman BM: AphaseIItrialof Taxotere (RP 56976) in ovarian cancer patients refractory to cis-platinlcarboplatin therapy. Proc ASCO 12:12, 1993.
  • New P: Neurotoxicity of Taxotere. Proc AACR 34:34, 1993.
  • Pazdur R, Newman RA, Newman BA, Fuentes A, Benvenuto J, BreadyB,MooreD,JaiyesimiI, VreelandF,Bayssas,RaberMN: Phase I trial of Taxotere: five day schedule. J Natl Cancer Inst 84:1781–1788, 1992.
  • Piccart MJ, Gore M, Ten Bokkel Huinink W, Wan Oosterom A, Verweij J, Kaye S, Wander J, Franklin H: Taxotere. An active new drug forthe treatmentof advancedovariancarcinoma. ProcASCO 12:12, 1993.
  • Wanders J, Schrijvers D, Bruntsch LJ,Gore M, Verweij J, Hanauski AR,FranklinH,RoelvinkM, BayssasM, KayeSB:TheEORTC-ECTCexperiencewithacutehypersensitivity reactionsinTaxotere studies. Proc ASCO 12:12, 1993.

BIBLIOGRAPHY

  • Fumoleau P, Chevallier B. Kerbrat P, Dieras V, LeBail N, Bayssas M, VanGlabbeke M: First line chemotherapy with taxotere (T) in advanced breast cancer (ABC): a phase II study of the EORTC clinical screening group (CSG). American Society of Clinical Oncology (ASCO), ProcASCO 1993, 12:12 (abstract 27).
  • Piccart MJ: Taxotere: a second generation taxoid compound. ASCO Educational Book 1993:25–32.
  • Seidman AD, Hudis C, Crown JPA, Balmaceda C, Lebwohl D, Currie V, Gilewski T. Hakes T, Robles M, Klem K. Lepore J. Norton L: Phase II evaluation of taxotere (RP56976. NSC628503) as initial chemotherapy for metastatic breast cancer. American Society of Clinical Oncology (ASCO), ProcASCO 1993, 12:12 (abstract 52).
  • Trudeau M. Eisenhauer E. Lofters W, Norris B, Muldal A, Letendre F, Vandenburg T, Verma S: Phase II study of taxotere as first line chemotherapy for metastatic breast cancer (MBC). National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) study. American Society of Clinical Oncology (ASCO). Prco ASCO 1993. 12:12 (abstract 59).

References

  • Demetri G, Younger J, Shapiro C, Douville L, Colecchi C, Armstrong S, McGuire B, Henderson IC: A phase I study of dose-intensified CAF chemotherapy with adjunctive r-met HuG-CSF (GCSF) in patients with advanced breast cancer. Proc ASCO 11: 108, 1992 (abstract 255).
  • Bronchud MH, Howell A, Crowther D, Hopwood P, Souza L, Dexter TM: The use of granulocyte colony-stimulating factor to increase the intensity of treatment with doxorubicin in patients with advanced breast and ovarian cancer. Br J Cancer 60: 121–125, 1989.
  • Henderson IC, Allegra JC, Woodcock T, Wolff S, Bryan S, Cartwright K, Dukart G, Henry D: Randomized clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer. J Clin Oncol 7:560–571, 1989.
  • Demetri GD, Hayes DF, Shapiro C, Parker L, Merica EA, Henderson IC: Dose-intensification of mitoxantrone with adjunctive GCSF (filgrastim) in patients with advanced breast cancer: a phase I trial. Blood 80 (suppl 1):292a, 1992 (abstract 1159).

BIBLIOGRAPHY

References

  • Levine AJ, Momand J, Finlay CA: The p53 tumor suppression gene. Nature 351:453–456, 1991.
  • Shay JW, Werbin H, Funk WD. Wright WE: Cellular and molecular advances in elucidating p53 function. Mutation Res 277:163–171, 1992.
  • Ulrich SJ. Anderson CWo Mercer WE. Apella E: The p53 tumor suppressor protein. a modulator of cell proliferation. J Cell BioI Chern 267:15259-15262, 1992.
  • Gannon JV, Greaves R, Iggo R. Lane DP: Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. EMBO J 9:9–1602,1990.
  • Nigro JM. Baker SJ, Preisinger AC, et al: Mutations in the p53 gene occur in diverse human tumor types. Nature 342:705–708, 1989.
  • Cossman J, Schlegel R: p53 in the diagnosis of human neoplasia. J Natl Cancer Inst 83:980–981, 1991.
  • Holstein M. Sidransky D, Vogelstein B. Harris CC: p53 muta-tions in human cancers. Science 253:253–49, 1991.
  • Sarnow P, Ho YS, Williams J, Levine AJ: Adenovirus Elb-58 kd tumor antigen and SV40 large tumor antigen are physically associated with the same 54 kd cellular protein in transformed cells. Cell 28:387–394, 1982.
  • Momand J, Zambetti Gp, Olson OC. George D. Levine AJ: The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69:1237–1245, 1992.
  • Cattoretti G, Rilke F. Andreola S. et al: p53 expression in breast cancer. Int J Cancer 41:41–178. 1988.
  • Allred OC, Clark GM, Elledge R, et al: Association of p53 pro-tein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst 85:85, 1993.

BIBLIOGRAPHY

  • Friedel A, Jordan VC, Pollak M: Reduction in serum IGF-I levels following commencement of tamoxifen therapy. Eur J Cancer, (in press, 1993).
  • Huynh H, Tetenes E, Wallace L, Pollak M: In vivo inhibition of IGF-I gene expression by tamoxifen. Cancer Res 53:53–1727, April 15,1993.
  • Pollak M: Therapeutic implications of growth factor research. In High Risk Breast Cancer (1. Ragaz, ed), Springer-Verlag, New York, 1990.
  • Pollak M: Timing of surgery in breast cancer, Lancet 337:337, 1991.
  • Pollak M: Effects of adjuvant tamoxifen therapy on growth hormone and IGF-I physiology. In Adjuvant Therapy ofCancer VII (Salmon S, ed). Lipincott, Philadelphia, 1993.
  • Pollak M, Costantino J, Polychronakos C, Blauer S, Guyda H, Redmond C, Fisher B, Margolese R: Effects of tamoxifen on serum IGF-I levels of stage I breast cancer patients. J Natl Cancer Inst 82:82–1693,1990.
  • Pollak M, Gora P, Boyarsky A: A mathematical model describing con-sequences of abnormally high levels of epidermal growth factor receptor on the proliferation of neoplastic cells. Cancer Invest 9(5), 513-520, 1991.
  • Pollak M, Hung The Huynh, Lefebvre S: Tamoxifen reduces serumlike growth factor I (lGF-I). Breast Cancer Res Treatment 22:22–100, 1992.
  • Pollak M, Malaab S, Goodyer C: Direct effects of tamoxifen on growth hormone secretion by pituitary cells in vitro. Eur J Cancer, 28A:788-793, 1992.
  • Pollak M, Poisson R, Galant K: Potential role for the somatostatin analogue sandostatin in breast cancer: rationale and description of an ongoing trial. Metabolism, 41(9, suppl. 2): 119-120, 1992.
  • Pollak M, Sen A, Richard M, Tetenes E, Bell R: Inhibition of metastatic behavior of murine osteosarcoma by hypophysectomy. J Natl Cancer lnst 84:84–966, 1992.
  • Tannenbaum G, Pollak M: Tamoxifen attenuates pulsatile GH secretion: mediation in part by somatostatin. Endocrinology, 130 (6):788-793, 1992.

References

  • Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 339:339–1,71-85, 1992.
  • Ravdin PM, Green S, Dorr TM, McGuire WL, Fabian C, Pugh Rp, Carter RD, Rivkin SE, Borst JR, Belt RJ, et al: Prognostic significance of progesterone receptor levels in estrogen receptorpositive patients with metastatic breast cancer treated with tamoxifen: Results of a prospective Southwest Oncology Group study. J Clin Oncol 10(8):1284–91, 1992.
  • McGuire WL, Chamness GC, Fuqua SA: The importance of nor-mal and abnormal oestrogen receptor in breast cancer. Cancer Surveys 14:31–40, 1992.
  • Allred DC: Should immunohistochemical examination replace biochemical hormone receptor assays in breast cancer? Am J Clin Pathol99(l):1-3, 1993.

References

  • Buzdar ALJ,Kau SW, Smith TL, Hortobagyi ON: Ten-year results of FAC adjuvant chemotherapy trial in breast cancer. Am J Clin Oncol 12:123–128, 1989.
  • Buzdar ALJ,Kau SW, Hortobagyi ON, et al: Clinical course of patients with breast cancer with ten or more positive nodes who were treated with doxorubicin-containing adjuvant therapy. Cancer 69:448–452, 1992.
  • Hortobagyi ON, Buzdar AU: Locally advanced breast cancer: a review including the M. D. Anderson experience. In Ragaz J and Ariel 1M (Eds) High-Risk Breast Cancer, (Ragaz J, Ariel 1M, eds), pp. 382-415. Springer-Verlag, Berlin, 1991.
  • Hortobagyi ON, Ames FC, Buzdar ALJ,et al: Management of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapy. Cancer 62:2507–2516, 1988.

References

  • Norton L, Simon R: The Norton-Simon hypothesis revisited. Cancer Treat Rep 70:70–163, 1986.
  • Valeriote F, van Putten L: Proliferation-dependent cytotoxicity of anticancer agents: A review. Cancer Res 35:35, 1975.
  • Hug V, Johnston D, Finders M, Hortobagyi G: Use of growthstimulating hormones to improve the in vitro therapeutic index of doxorubicin for human breast cancer. Cancer Res 46:46, 1986.
  • Lippman ME. Hormonal stimulation and chemotherapy for breast cancer (editorial). J Clin Oncol 5:5, 1987.
  • Swain SM, Sorace RA, Bagley CS, Danforth DN: Jr., Bader J, Wesley MN, Steinberg SM, Lippman ME: Neoadjuvant chemotherapy in the combined modality approach of locally advanced nonmetastatic breast cancer. Cancer Res 47:47, 1987.
  • Osborne CK, Kitten L, Arteaga CL: Antagonism of chemotherapy-induced cytotoxicity for human breast cancer cells by antiestrogens. J Clin Oncol 7:7, 1989.
  • Bonadonna G, Valgussa P, Santoro A: Alternating noncrossresistant combination chemotherapy or MOPP in stage IV Hodgkin's disease. Ann Int Med 104:104, 1986.
  • Meyer JS, Prey MLJ,Babcock DS, McDivitt RW: Breast Carcinoma cell kinetics, morphology, stage, and host characteristics. A thymidine labeling study. Lab Invest 54:54, 1986.
  • Silvestrini R, Daidone MG, Valagusa P, Salvadori B, Rovini D, Bonadonna G: Cell kinetics as a prognostic marker in locally advanced breast cancer. Cancer Treat Rep 71:71, 1987.
  • Dressler LG: DNA flow cytometry measurements have significant prognostic impact in the node negative breast cancer patient: An intergroup study (INT 0076) In Treatment of Early Stage Breast Cancer: Program and Abstracts, pp. 99-101. NIH Consensus Development Conference, National Cancer Institute and the Office of Medical Applications of Research of the National Institutes of Health, June 18-21, 1990 (Abstract).
  • Lippman ME, Dickson RB: Growth control of normal and malignant breast epithelium. In Effects of Therapy on Biology and Kinetics of the Residual Tumor. Part A: Pre-Clinical Aspects (Ragaz J, Simpson-Herren J, Lippman ME, Fisher B., eds.), pp. 147-178. Wiley-Liss, New York, 1990.
  • Norton L: Biology of residual breast cancer after therapy: A kinetic interpretation. In Effects ofTherapy on Biology and Kinetics of Residual Tumor. Part A: Pre-Clinical Aspects (Ragaz J, ed.), pp. 109-132. Wiley, New York, 1990.
  • Lippman ME, Dickson RB, Bates S, Knabbe C, Huff K, Swain S, McManaway M, Bronzert D, Kasid A, Gelmann EP: Auto-crine and paracrine growth regulation of human breast cancer. Breast Cancer Res Treat 7:7, 1986.
  • Anonymous: Adjuvant systemic therapy for early breast cancer (editorial). Lancet 339:339, 1992.
  • Zuckiet G, Tritton TR: Adriamycin causes up-regulation of epidermal growth factor receptors in actively growing cells. Exp Cell Res 148:148, 1983.
  • Isonishi S, Andrews PA, Howell SB: Increased sensitivity to cisdiamminedichloroplatinum (II) in human ovarian carcinoma cells in response to treatment with 12-0-tetradecanoylphorbol13-acetate. J Bioi Chem 265:265, 1990.
  • Masui H, Kawamoto T, Sato JD, Wolf B, Sato G, Mendelsohn J Growth inhibition of human tumor cells in athymic mice by antiepidermal growth factor receptor monoclonal antibodies. Cancer Res 1984, 44:44.
  • Baselga J, Norton L, Masui H, Pandiella A, Coplan K, Miller WH Jr., Mendelsohn 1. Anti-tumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibody. J Natl Cancer Inst (in press, 1993).

References

  • Ahmann DL, Creagan ET, Hahn RG, et al: Complete responses and long-term survivals after systemic chemotherapy for patients with advanced malignant melanoma. Cancer 63:63, 1989.
  • Morton DL, Eilber FR, Holmes EC, Ramming KP: Preliminary results of a randomized trial of adjuvant immunotherapy in patients with malignant melanoma who have lymph node metastases. Aust N Z J Surg 48:48, 1978.
  • Morton DL, Foshag LJ, Nizze lA, et al: Active specific immunotherapy in malignant melanoma. Semin Surg Oneal 5:5, 1989.
  • Morton DL. Hoon DSB, Foshag LJ,et al: Active immunotherapy of metastatic melanoma with melanoma vaccine immunomodulation. Proc Am Assoc Cancer Res 32:32, 1991.
  • Morton DL, Foshag LJ,Hoon DSB, et al: Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine. Ann Surg 216:216, 1992.
  • Morton DL, Hoon DSB, Gupta RK, et al: Treatment of malignant melanoma by active specific immunotherapy in combination with biological response modifiers. In New Horizons of Tumor Immunotherapy (Torisu M, Yoshida T, eds.), p. 665. Elsevier Science Publishers B.V. (Biomedical Division), Amsterdam, 1989.
  • Hoon DSB, Foshag LJ,Nizze AS, et al: Suppressor cell activity in a randomized trial of patients receiving active specific immunotherapy with melanoma cell vaccine and low dosages of cyclophosphamide. Cancer Res 50:50, 1990.
  • Morton DL, Eilber FR, Holmes EC, et al: BCG immunotherapy of malignant melanoma: summary of a seven-year experience. Ann Surg 180:180, 1974.
  • Hoon DSB, Banez M, Okun E, et al: Modulation of human melanoma cells by interleukin-4 and in combination with gammainterferon or alpha-tumor necrosis factor. Cancer Res 51:51, 1991.

References

  • Abdel-Nabi H, Doerr RJ: Radiolabeled monoclonal antibody imaging (immunoscintigrapby) of.colorectal cancers: current status and future perspectives. Am J Surg 163:448–456, 1992.
  • Patt YZ, Lamki LM, Shaken J, et al: Imaging with indium-lIllabeled anticarcinoembryonic antigen monoclonal antibody ZCE-025 in patients with rising serum careinoembryonic antigen levels and occult metastases. J Clin Oncol 8:1246–1254, 1990.
  • Thor A, Ohuchi N, Szpak CA, et al:Distribution of oncofetal an-tigen tumor-associated glycoprotein-72 defined by monoclonal antibody B72.3. Cancer Res 46:3118-3124. 1986.
  • Rodwell JD. Alvarez VL, LeeC: Site specific covalent modifica-tion of monoclonal antibodies: in vitro and in vivo evaluations. PNAS 83:2632–2636, 1986.
  • Collier BD. Abdel-Nabi H, Doerr RJ et al:Immunoscintigraphy performed with In-Ill-labeled CYT-103 in the management of colorectal cancer: Comparison with CT. Radiology 185:179–186, 1992.
  • Weiner GJ, Kahn D, Jochimsen PR et al: Radiolabeled antibody imaging of patients with potentially resectable recurrent colorectal adenocarcinoma. Cancer Invest (in press).

BIBLIOGRAPHY

  • Burt RW, Groden J: The genetic and molecular diagnosis of adenomatous polyposis coli. Gastroenterology 104:1211–1214, 1993.
  • Cannon-Albright LA, Skolnick MH, Bishop DT, et al: Common inheritance of susceptibility to colonic adenomatous polyps and associated colorectal cancers. N Engl J Med 319:533–537, 1988.
  • Leppert M, Burt R, Hughes lP, et al: Genetic analysis of an inherited predisposition to colon cancer in a family with a variable number of adenomatous polyps. N Engl J Med 322:904–908, 1990.
  • Lynch HT, Smyrk TC, Watson P, et al: Genetics, natural history, tumor spectrum, and pathology of hereditary nonpolyposis colorectal cancer: an updated review. Gastorenterology 104:1535–1549, 1993.
  • Paltomaki P, Aaltonen LA, Sistonen P, et al: Genetic mapping of a locus predisposing to human colorectal cancer. Science 260:260, 1993.

References

  • Schally AV: Oncological applications of somatostatin analogues. Cancer Res 48:6977–6985, 1988.
  • Reubi J-C, Krenning E, Lamberts SWJ, Kvols L: Somatostatin receptors in malignant tissues. J Ster Biochem Mol Bioi 37:1073–1077, 1990.
  • Liebow C, Reilly C, Serrano M, Schally AV: Somatostatin analogues inhibit growth of pancreatic cancer by stimulating tyrosine phosphatase. Proc Natl Acad Sci USA 86:2003-2007, 1989.
  • Singh P, Townsend CM Jr, Poston OJ, Reubi J-C: Specific binding of cholecystokinin, estradiol and somatostatin to human pancreatic cancer xenografts. J Steroid Biochem Molec Bioi 39:759–767, 1991.
  • Schally AV,Coy DH, Murpy WA et al: Physiological and clinical studies with somatostatin analogs and pro-somatostatin. In: Second International Symposium on Somatostatin. Athens, pp. 188-196. (Raptis S, Rosenthal J, Gerich JE, eds), Attempto Verlag, 'Iubingen, Germany, 1984.
  • Plewe G, Beyer J, Krause LJ,Neufeld M, Del Pozo E: Long act-ing and selective suppression of growth hormone secretion by somatostatin analogue SMS 201-995 in acromegaly. Lancet 2.782-784, 1984.
  • Kvols LD: Metastatic carcinoid tumors and the carcinoid syn-drome. Am J Med 81(suppl 6B):49-53, 1986.
  • Mathe G, Gastiaburu J, Comaru-Schally AM, et al: Octastatine, an agonist of somatostatin. In Second International Conference ofthe Metastasis Research Society, Heidelberg, Germany, 1988.
  • Liebow C, Hierowski M, DuSapin K: Hormonal control of pan-creatic cancer growth. Pancreas 1:44–48, 1986.
  • Hierowski MT, Liebow C, DuSapin K et al: Stimulation by so-matostatin of dephosphorylation of membrane proteins in pancreatic cancer MIA PaCa-2 cell lines. FEBS Lett 179:252–256, 1985.
  • Liebow C, Lee MT, Schally A: Antitumor effects of somatostatin mediated by the stimulation of tyrosine phosphatase. Metabolism 39:163–166, 1990.
  • Poston OJ, Gillespie J, Guillou PJ: Biology of pancreatic cancer. Gut 32:800–812, 1991.
  • Redding TW, Schally AV: Inhibition of growth of pancreatic car-cinomas in animal models by analogs of hypothalamic hormones. Proc Natl Acad Sci USA 81:248–252, 1984.
  • Szende B, Zalatnai A, Schally AV: Programmed cell death (apoptosis) in pancreatic cancers of hamsters after treatment with analogs of both luteinizing hormone-releasing hormone (LH-RH) and somatostatin. Proc Natl Acad Sci USA 86: 16431647, 1989.
  • Szende B, Srkalovic G, Schally AV, et al: Inhibitory effects of analogs of luteinizing hormone-releasing hormone and somatostatin on pancreatic cancers in hamsters: events that accompany tumor regression. Cancer 65:2279–2290, 1990.
  • Zalatnai A, Schally AV: Responsiveness of the hamster pancre-atic cancer to treatment with microcapsules of 0-Trp-6-LH-RH and somatostatin analog RC-I60: histological evidence of improvement. Int J PancreatoI4:4–149O, 1989.
  • Upp JR Jr, Olsen D, Poston GJ, et al: Somatostatin analog SMS 201-995 inhibits the growth of two human pancreatic adenocarcinomas in vivo. Am J Surg 155:29–35, 1988.
  • Radulovic S, Comaru-Schally AM, Milovanovic S, Schally AV: Somatostatin analog RC-I60 and LH-RH antagonist SB-75 inhibit growth of MIA PaCa-2 human pancreatic cancer xenografts in nude mice. Pancreas (in press, 1992).
  • Szepeshazi K, Schally AV, Cai A-Z et al: Inhibitory effect of bombesinlgastrin-releasing peptide antagonist RC-3095 and high dose somatostatin analogue RC-I66 on nitrosamine-induced pancreatic cancers in hamsters. Cancer Res 51:5980–5986, 1991.
  • Szepeshazi K, Lapis K, Schally AV: Effect of combination treatment with analogs of luteinizing hormone-releasing hormone (LH-RH) or somatostatin and 5-fluorouracil on pancreatic cancer in hamsters. Int J Cancer 49:260–266, 1991.
  • Radulovic S, Nagy A, Szoke B, Schally AV:Cytotoxic analog of somatostatin containing methotrexate inhibits growth of MIA PaCa-2 human pancreatic cancer xenografts in nude mice. Cancer Lett (in press 1992).
  • Poston GJ, Townsend CM Jr, Thompson JC, Singh P: Effect of somatostatin and tamoxifen on the growth of human pancreatic cancers in nude mice. Pancreas 5:151–157, 1990.

BIBLIOGRAPHY: ADDITIONAL CLINICAL REFERENCES ON SOMATOSTATIN ANALOGS FOR NEUROENDOCRINE TUMOR THERAPY

  • Krenning Ep, Bakker WH, Breeman WAp, et al: Localization of endocrine-related tumours with radio-iodinated analogue of somatostatin. Lancet i:242-244, 1989.
  • Lamberts SWJ, Bakker WH, Reubi JC, and Krenning EP: Somatostatin receptor imaging: in vivo localization of tumors with a radiolabelled somatostatin analog. J Steroid Biochem Molec Biol 37: 1079–1082, 1990.
  • Reubi JC, Kvols LK, Waser B, et al: Detection of somatostatin receptors in surgical and percutaneous needle biopsy samples of carcinoids and islet cell carcinomas. Cancer Res 50:5969–5977, 1990.
  • Reubi JC, Landolt AM: The growth hormone responses to Octreotide in acromegaly correlate with adenoma somatostatin receptor status. J Clin Endocr Metab 68:844–850, 1989.
  • Reubi JC, Maurer R, von Werder K, et al: Somatostatin receptors in human endocrine tumors. Cancer Res 47:551–558, 1987.

References

  • Jackman AL, Taylor GA. Gibson W. et al: ICI 01694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of LI210 tumour cell growth in vitro and in vivo: a new agent for clinical study. Cancer Res 51:5579-5586. 1991.
  • Judson I, Clarke S, Ward J, et al: Pharmacokinetics (PK) of ICI D1694 following a 15 minute infusion in patients with advanced cancer. Proc Am Soc Clin Oncolll:117, 1992.

References

References

  • Huang Y, Waxman S: Synergistic induction of apoptosis (APO) by combination cytotoxic-differentiation therapy (CCDT). Proc Am Assoc Cancer Res 34:34, 1993.
  • Waxman S. Scher, BM, Hellinger N, and Scher W: Combination cytotoxic-differentiation therapy of mouse erythroleukemia cells with 5-f1uorouracil and hexamethylene bisacetamide. Cancer 50:3878–3887, 1990.
  • Waxman S. Huang Y. Scher BM, Scher W: Enhancement of differentiation and cytotoxicity of leukemia cells by combinations of fluorinated pyrimidines and differentiation inducers; development of DNA double-strand breaks. Biomed Pharmacother 46:46, 1992.
  • Wu H, Scher BM, Chu L, Leonard M. Olmedo R, Scher OS, Stecker S, Scher W, Waxman S: Reduction in lactate accumula-tion correlates with differentiation-induced terminal cell division of leukemia cells. Differentiation 48:51–58, 1991.

References

  • Stolfi RL, Colofiore JR, Nord LO, Koutcher JA, Martin OS: Bio-chemical modulation of tumor cell energy: regression of advanced spontaneous murine breast tumors with a 5-fluorouracilcontaining drug combination. Cancer Res 52:4074–4081, 1992.
  • Kemeny NE, Costa P: Phase II trial of PALA and FU in meta-static colorectal carcinoma. Proc Am Soc Clin Oncol 10:10.
  • O'Dwyer Pl, Hudes GR, Colofiore J, Walczak J, Hoffman J, LaCreta FP, Comis RL, Martin OS, Ozols R: Phase I trial of fluorouracil modulation by N-phosphonacetyl-L-aspartate and 6-methylmercaptopurine riboside: optimization of 6-methylmer-captopurine riboside dose and schedule through biochemical analysis of sequential tumor biopsy specimens. J Natl Cancer Inst 83:1235-1240, 1991.
  • Casper E, et al: Memorial Sloan-Kettering Cancer Center, New York, NY.
  • Martin DS, Stolfi RL, Colofiore JR, Nord LO, Sternberg S: Biochemical modulation of tumor cell energy in vivo: II. a lower dose of adriamycin is required and a greater antitumor activity is induced when cellular energy is depressed. (submitted for publication).
  • Koutcher JA, Alfieri AA, Stolfi RL, Devitt ML, Colofiore JR, Martin DS: Potentiation of a three drug chemotherapy regimen by radiation. Cancer Res (in press).

References

  • Drewinko B, Yang, LY: Cellular basis for the inefficacy of 5fluorouracil in human colon carcinoma. Cancer Treat Rep 69:1391-1398,1985.
  • MacMillan WE, Wolberg WH, Welling PO: Pharmacokinetics of Sfluorouracil in humans. Cancer Res 38:3479–3482, 1978.
  • Seifert P, Baker LH, Reed MO, et al: Comparison of continuously infused 5-fluorouracil with bolus injection in patients with colorectal adenocarcinoma. Cancer 36:123–128. 1975.
  • Lokich JJ, Ahlgren JD. Gullo JJ, et al: A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma. J Clin Oncol 7:425–432, 1989.
  • Hansen R, Ryan L, Anderson T, et al: A phase III trial of bolus 5FU versus protracted infusion 5FU: tcisplatin in metastatic colorectal cancer. an Eastern Cooperative Oncology Group study (Est 2286). Proc Am Soc Clin Oncol II, 1992, (abstract).
  • Rougier PH, Paillot B, Laplanche A, et al: End results of a mul-ticentric randomized trial comparing 5FU in continuous systemic infusion (CI) to bolus administration (B) in measurable metastatic colorectal cancer (MCC). Proc Am Soc Clin Oncol II, 1992 (abstract).
  • Weinerman B, Shah A, Fields A, et al: A randomized trial of continuous systemic infusion versus bolus therapy with 5fluorouracil in metastatic measurable colorectal cancer. Proc Am Soc Clin Oncol 3:3, 1990 (abstract).
  • Lokich J, Anderson N: Controversial issues in 5fluorouracil in-fusion use. dose intensity, treatment duration and cost comparisons. Cancer 70:998-1002, 1992.
  • Leichman CG, Fleming TR, Muggia FM, Ardalan B, Doroshow J. Tangen C, MacDonald J: Fluorouracil (5FU) schedules and modulation in advanced colorectal cancer (CRC): a Southwest Oncology Group (SWOG) screening trial. Proc ASCO, 1993 (583).
  • Grem JL: The KobayashiiSchilsky article reviewed. Oncology 7:7–110, 1993.
  • Wolmark N, Rockette H, Wickerham DL, et al: adjuvant therapy of Dukes' A, B and C adenocarcinoma of the colon with portalvein hepatic infusion: preliminary results of National Surgical Adjuvant Breast and Bowel Project protocol C-02. J Clin Oncol 8:1466–1475, 1990.
  • O'Connell M, Martenson J, Rich T, Weiand H, Krook J, Mac-Donald J, Haller D, Mayer R, Gunderson L: Protracted venous infusion (PVI) 5f1uorouracil (5FU) as a component of effective combined modality postoperative surgical adjuvant therapy for high-risk rectal cancer. Proc ASCO 1993, 564.

References

  • Sallan SE, Hitchcock-BryanS. Gelber R. Cassady JR. Frei E III. Nathan DG: Influence of intensive asparaginase in the treatment of childhood non-T-cell acute lymphoblastic leukemia. Cancer Res 43:5601–5607. 1983.
  • Amylon MD, Carroll AJ. Link MP. Katz JA. Shuster 11: Second malignancies in children treated with Teniposide (VM-26) for Tcell lymphoid malignancy: a role for asparaginase? [a Pediatric Oncology Group (POG) Study]. Blood 80:80a 1992 (abstract 815).
  • Kurtzburg J. Asselin B. Poplack D. et al: Antibodies to asparagi-nase alter pharmacokinetics and decrease enzyme activity in patients on asparaginase therapy. Proc Am Assoc Cancer Res 34:34. 1993 (abstract 1807).

References

  • Miller T. Grogan T. Dalton W. et al: P-glycoprotein expression in malignant lymphoma and reverse of clinical drug resistance with chemotherapy plus high-dose verapamil. J Clin Oncol 9:9–17. 1991.
  • Haubermann K, Benz B, Gekeler V, Schumacher K. Eichelbaum M: Effects of verapamil entantiomers and major metabolites on the cytotoxicity of vincristine and daunomycin in human lymphoma cell lines. Eur J Clin Pharmacol 40:53–59. 1991.
  • Wilson WH, Bryant G. Bates S. et al: EPOCH chemotherapy: toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma. J Clin Oncol 11:1573–1582. 1993.

References

  • Safa AR, Glover D, Meyers MB, et al: Vinblastine photoaffinity labeling of a high molecular weight surface membrane glycoprotein specific for multidrug-resistant cells. J Bioi Chern 261:6137–6140, 1986.
  • Cornwell M, Pastan I, Gottesman MM: Certain calcium channel blockers bind specifically to multidrug resistant human KB carcinoma membrane vesicles and inhibit drug binding to P-glycoprotein. J Bioi Chern 262:2166–2170, 1987.
  • Zamora JM, Pearce HL, Beck WT: Physical-chemical properties shared by compounds that modulate multidrug resis-tance in human leukemic cells. Mol Pharmacol 33:454–462, 1988.
  • Naito M, Tsuruo T: Competitive inhibition by verapamil of ATPdependent high affinity vincristine binding to the plasma membrane of multidrug-resistant K562 cells without calcium ion involvement. Cancer Res 49:1452–1455, 1989.
  • Tsuruo T, Iida H, Tsukagoshi S, et al: Increased accumulation of vincristine and adriamycin in drug-resistant P388 tumor cells following incubation with calcium antagonists and calmodulin inhibitors. Cancer Res 42:4730–4733, 1982.
  • Nooter K, Oostrom R, Jonker R, et al: Effect of cyclosporin A on daunorubicin accumulation in multidrug-resistant P388 leukemia cells measured by real-time flow cytometry. Cancer Chemother PharmacoI23:296–300, 1989.
  • Slater L, Sweet p, Stupecky M, et al: Cyclosporin A reverses vincristine and daunorubicin resistance in acute lymphatic leukemia in vitro. J Clin Invest 77:1405–1408, 1986.
  • Twentyman P, Fox N, White D: Cyclosporin A and its analogues as modifiers of adriamycin and vincristine resistance in a multidrug resistant human lung cancer cell line. Brit J Cancer 55:55,1987.
  • Meador J, Sweet P, Stupecky M, et al: Enhancement by cyclosporin A daunorubicin efficacy in Ehrlich ascites carcinoma and murine hepatoma 129. Cancer Res 47:6216–6219, 1987.
  • Ford JM, Hait WN: Pharmacology of drugs that alter multidrugresistance in cancer. Pharmacol Rev 42:155–199, 1990.
  • Benson AB, Trump DL, Koeller JM: Phase I study of vinblastine and verapamil given by concurrent IV infusion. Cancer Treat Rep 69:795–799, 1985.
  • Ozols RF, Cunnion RE, Klecker RWJ: Verapamil and adriamy-cin in the treatment of drug-resistant ovarian cancer patients. J Clin OncoI5: 64I-647, 1987.
  • Dalton WS, Grogan TM, Meltzer PS, et al: Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. J Clin Oncol 7:415–424, 1989.
  • Tamai I, Sara AR: Azidopine noncompetitiveIy interacts with vinblastine and cyclosporin A binding to P-glycoprotein in multidrug resistant cells. J Bioi Chern 266:16796–16800, 1991.
  • Tamai I, Saffa AR: Competitive interaction of cyclosporins with the Vinca alkaloid-binding site of P-glycoprotein in multidrugresistant cells. J BioI Chern 265:16509–16513, 1990.
  • Samuels BL, Rosemarie M, Vogelzang NJ, Williams SF, Schilsky RL, Safa AR, O'Brien SM, Ratain MJ: Modulation of vinblastine resistance with cyclosporine A: a phase I study. Clin Pharm Ther (in press).
  • Trump DL, Smith DC, Schold SC, et al: High dose tamoxifen and five day continuous infusion vinblastine: a phase I trial of an inhibitor or the MDR-I phenotype. Proc Am Soc Clin Oncol 10:10, 1991.
  • Samuels BL, Murray JL, Safa AR: Additive reversal of multidrug resistance by combinations of non-cross-toxic modulating agents. Proc Am Assoc Cancer Res 31:31, 1990.
  • Yap H-Y, Blumenschein GR, Keating MJ, et al: Vinblastine given as a continuous 5-day infusion in the treatment of refractory advanced breast cancer. Cancer Treat Rep 64:279–283, 1980.
  • Ratain MJ, Vogelzang NJ: Phase I and pharmacological study of vinblastine by prolonged continuous infusion. Cancer Res 46:4827–4830, 1986.
  • Ratain MJ, Vogelzang NJ, Sinkule JA: Interpatient and intrapa-tient variability in vinblastine pharmacokinetics. Clin Pharmacol Ther 41:61–67, 1987.
  • Gosland MP, Brophy NA, Duran GE, et al: Bilirubin: a physio-logical substrate for the multidrug transporter. Proc Am Assoc Cancer Res 32:32, 1991.
  • Yahanda AM, Adler KM, Hardy R, et al: A phase I trial of etop-oside with cyclosporine as a modulator of multidrug resistance. Proc Am Soc Clin Oncol 10:10, 1991.

References

  • Barlozzari T, Reynolds CW, Herberman RB: In vivo role of natural killer cells: involvementof large granular lymphocytes in the clearance of tumor cells in anti-asialo GMI-treated rates. J Immunol13I:1024-1027,1983.
  • Hiserodt JC, Britvan LJ,Targan SR. Characterization of the cytologic reaction mechanism of the human natural killer (NK) lymphocyte resolution into binding, programming, and killer cellindependent steps. J Immunol 129:1782–1787, 1982.
  • Foss OP, Brennohd 10, Messelt QT, Efskind J, Liverud K: Invasion of tumor cells into the bloodstream caused by palpation or biopsy of the tumor. Surgery 59:59–691, 1066.
  • Uchida A, Kolb R, Michsche M: Generation of suppressor cells for natural killer activity in cancer patients after surgery. J Natl Cancer Inst 68:735–741, 1982.
  • Pollock RE, Lotzova E, Stanford SO, Romsdahl MM: Effect of surgical stress on murine natural killer cell cytotoxicity. J Immunol 138:171–178, 1987.
  • Pollock RE, Lotzova E, Stanford SO: Surgical stress impairment of murine natural killer cell cytotoxicity involves pre-and postbinding events. J Immunol 143:3396–33403, 1989.
  • Pollock RE, Lotzova E: Surgical-stress-related suppression of natural killer cell activity; a possible role in tumor metastasis. Nat Immun Cell Growth Regul 6:269–278, 1987.
  • Liotta LA, Kleinerman J, Saidel GM: The Significance of hematogenous tumor cell clumps on the metastatic process. Cancer Res 36:889–894, 1976.
  • Simpson-Herren L, Springer TA, Sanford AH, Holmquist JP: Kinetics of metastases in experimental tumors. In Cancer Invasion and Metastasis: Biologic Mechanisms and Therapy (Day SB, ed), pp 117-133. Raven Press, New York, 1977.
  • Shiu MH, Brennan MF: Principles of surgical management. In Surgical Management of Soft Tissue Sarcoma (Shiu MH, Brennan MF, ed), pp 64-76. Lea and Febiger, Philadelphia, 1989.
  • Pollock RE, Lotzova E, Stanford SO: Surgical stress impairs natural killer cell programming of tumor for lysis in patients with sarcomas and other solid tumors. Cancer 70:2192–2202, 1992.

BIBLIOGRAPHY

  • Batist G, Mayer L, Pilkiewicz, et al: Liposomal doxorubicin in experimental and clinical breast cancer is effective and less toxic. Proc AACR 32:32, 1991.
  • Mayer L, Tai LCL, Ko DSC, et al: Influence of vesicle size, lipid com-position and drug-to-lipid ratio on the biological activity of liposomal doxorubicin. Cancer Res 49:5922, 1989.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.